AlertEdge.io
Single-Ticker Trade Brief
WAT — Waters Corporation Report Date: 2026-07-29 13:55 UTC  |  Sector: Health Care  |  Rating:
RISK DISCLAIMER: This is an momentum signal based on MACD and relative strength. Always validate before entering a position.
▲▲ Momentum Leader — MACD Cross + S&P 500 Outperformance

WAT has a bullish MACD crossover on daily bars and is outperforming the S&P 500 by +29.66% over the past 63 trading days (WAT +33.63% vs SPY +3.97%).

Ticker
WAT
Entry Price
$390.32
vs S&P 500 (63d)
+29.66%
Ticker Return
+33.63%
Stop Loss
$368.72
TP1 Target
$422.73
TP2 Target
$444.33
Risk / Reward
1 : 1.5
Daily ATR stop
View WAT Chart on TradingView

Key Price Levels

TP1 Target
$422.73
Breakout Level
$0
Entry
$390.32
Stop Loss
$368.72

Fundamentals

P/E Ratio
N/A
EPS (TTM)
N/A
Dividend Yield
0%
52-Wk High
N/A
52-Wk Low
N/A
Beta
N/A

Deep Dive Analysis — Claude Sonnet

ALERTEDGE TRADE BRIEF — WAT (Waters Corporation)

Generated Signal: Momentum Leader | Sector: Health Care

SETUP

WAT is breaking out with conviction. Price closed near session highs at $390.32 after a bullish MACD crossover on the daily chart, confirming momentum is accelerating. The stock has outperformed the S&P 500 by nearly 30% over the past 63 trading days, signaling institutional accumulation and genuine relative strength, not a dead-cat bounce. The risk/reward offers $32 downside to stop versus $54 to TP1 and $54 further to TP2. The entry bar shows buyers defending the open and pressing toward highs, a clean structure for continuation.

CATALYSTS

Earnings are the immediate driver to watch. Multiple analyst notes are circulating around whether WAT can beat estimates again, suggesting a positive earnings revision cycle may be underway. Waters generates meaningful recurring revenue through its instrument service contracts and consumables, which tend to be sticky and margin-accretive. The biopharma and life science tools sector has been quietly recovering as large pharma capital spending stabilizes post-inventory destocking cycle from 2023. If that tailwind holds, WAT has room to continue repricing higher. Any guidance raise on recurring revenue would be a strong catalyst.

RISKS

Earnings are a double-edged sword here. Buying into a run ahead of results means gap-down risk if the report disappoints or guidance is cautious. The signal quality score of 50 out of 100 is a yellow flag, indicating this is not an early-in-move setup. The stock has already moved substantially, and entering now carries extension risk. Fundamentals data is incomplete, making valuation assessment difficult. Volume on this bar is very thin at 3,448 shares, which raises questions about conviction behind the move. A close back below $384 would weaken the structure immediately.

CONVICTION: Medium

The relative strength and MACD confirmation are genuine positives, but the average signal quality score, thin volume on the breakout bar, and earnings binary risk limit confidence in chasing this entry at current levels.

TRADE PARAMETERS

Entry: $390.32

Stop: $368.72

TP1: $422.73

TP2: $444.33

R/R: 1:1.5 to TP1